(Total Views: 482)
Posted On: 06/23/2019 11:29:50 AM
Post# of 155026
NP said in the latest video end of June to 2nd week of July for first injection.
Yes, they are connecting three technologies, an proven one, chemo drug Carboplatin, with two new technologies: CCR5 (leronlimab) and CTC as a liquid biopsy (CTC).
Both Prestel and Cristofanilli have planed for years and have a lot of the line with this trial. The must feel very confident in leronlimab with TNBC, because it is the first (poster child) to prove both technologies. I'm sure there has been lots of different ideas in the best way to connect these technologies and it has taken longer than they expected to get everything set up perfectly.
Prestell gave his IP with ccr5 with cancer and the ProstaGene™ Prognostic Prostate Cancer Test for a seat at the table. We will see how that license deal goes, if they get more cash for the deal, then the entire purchase of ProstaGene, basically they would get the cancer+ccr5 patent for free. Maybe the deal of the decade in cancer research, we will see.
Cristofanilli, father of CTC, technology, has life work research in this area. See the Vita for Cristofanilli,
https://www.fda.gov/media/117382/download
Yes, they are connecting three technologies, an proven one, chemo drug Carboplatin, with two new technologies: CCR5 (leronlimab) and CTC as a liquid biopsy (CTC).
Both Prestel and Cristofanilli have planed for years and have a lot of the line with this trial. The must feel very confident in leronlimab with TNBC, because it is the first (poster child) to prove both technologies. I'm sure there has been lots of different ideas in the best way to connect these technologies and it has taken longer than they expected to get everything set up perfectly.
Prestell gave his IP with ccr5 with cancer and the ProstaGene™ Prognostic Prostate Cancer Test for a seat at the table. We will see how that license deal goes, if they get more cash for the deal, then the entire purchase of ProstaGene, basically they would get the cancer+ccr5 patent for free. Maybe the deal of the decade in cancer research, we will see.
Cristofanilli, father of CTC, technology, has life work research in this area. See the Vita for Cristofanilli,
https://www.fda.gov/media/117382/download
(1)
(0)
